NovoCure Ltd (MEX:NVCR)
MXN 275.39 0 (0%) Market Cap: 37.39 Bil Enterprise Value: 31.76 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 12:10PM GMT
Release Date Price: MXN535
Maxwell Skor

Okay. Great. Hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan Stanley. Before we get started, I just need to read an important disclosure. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures.

Great. I would like to welcome Bill Doyle, Executive Chair; and Ashley Cordova, CFO of Novocure. For those of us who are either new or revisiting the Novocure story, let's start off with the discussion of the base business, followed by an overview of LUNAR and next steps in non-small cell lung cancer and finally future opportunities.

Questions & Answers

Maxwell Skor

So to start off with, can you briefly introduce Optune and a theory behind Tumor Treating Fields.

William F. Doyle
NovoCure Limited - Executive Chairman

Sure. So first, let me say good morning,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot